Reduction of PPARα expression in the liver of patients with fatty livers has been reported; PPARα agonists, such as resveratrol, naringenin, trans-caryophyllene, and quercetin, are known to improve fatty liver disease and nonalcoholic fatty liver disease [60,61]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.